Biosse-Duplan Martin, Baroukh Brigitte, Dy Michel, de Vernejoul Marie-Christine, Saffar Jean-Louis
EA 2496, CNRS, Université Paris Descartes, Paris, France.
Am J Pathol. 2009 Apr;174(4):1426-34. doi: 10.2353/ajpath.2009.080871. Epub 2009 Mar 5.
In addition to the numerous roles of histamine in both the immune and nervous systems, previous studies have suggested that this bioamine might also be involved in bone metabolism. Following our observations of impaired bone resorption in ovariectomized rats after histamine receptor antagonist treatment, we focused in this study on osteoclasts and osteoclast precursors. We looked for a direct action of histamine on these cells using both in vivo and in vitro approaches. In vivo, we triggered a remodeling sequence in rat mandibular bone and treated the animals with either histamine or histamine receptor antagonists. Histamine was shown to increase the number of osteoclasts and osteoclast precursors whereas antagonists of histamine receptor-1 and -2 decreased both osteoclast recruitment and resorption. In vitro, spleen cells from histamine-deficient mice were treated with receptor activator for nuclear factor kappa B ligand and macrophage colony stimulating factor, giving rise to both reduced numbers of osteoclasts and decreased resorption on dentin slices. Histamine enhanced resorption in these cultures in a dose-dependent manner. In addition, we identified osteoclast precursors as a source of histamine. In contrast, histamine increased the receptor activator for nuclear factor kappa B ligand/osteoprotegerin ratio in primary osteoblasts that did not secrete histamine. We observed a differential expression of histamine receptor-1 and -2 mRNAs in both primary osteoclasts and osteoblasts, confirming their functional roles with selective antagonists. Thus, histamine acts directly on osteoclasts, osteoclast precursors, and osteoblasts, promoting osteoclastogenesis through autocrine/paracrine mechanisms.
除了组胺在免疫系统和神经系统中发挥的众多作用外,先前的研究表明,这种生物胺可能还参与骨代谢。在我们观察到组胺受体拮抗剂治疗后去卵巢大鼠的骨吸收受损后,本研究聚焦于破骨细胞和破骨细胞前体。我们使用体内和体外方法寻找组胺对这些细胞的直接作用。在体内,我们在大鼠下颌骨引发重塑序列,并用组胺或组胺受体拮抗剂处理动物。结果显示,组胺可增加破骨细胞和破骨细胞前体的数量,而组胺受体 -1 和 -2 的拮抗剂则可减少破骨细胞募集和骨吸收。在体外,用核因子κB 受体活化因子配体和巨噬细胞集落刺激因子处理组胺缺陷小鼠的脾细胞,导致破骨细胞数量减少以及牙本质切片上的骨吸收降低。组胺以剂量依赖性方式增强这些培养物中的骨吸收。此外,我们确定破骨细胞前体是组胺的来源。相比之下,组胺增加了未分泌组胺的原代成骨细胞中核因子κB 受体活化因子配体/骨保护素的比例。我们观察到组胺受体 -1 和 -2 mRNA 在原代破骨细胞和成骨细胞中均有差异表达,用选择性拮抗剂证实了它们的功能作用。因此,组胺直接作用于破骨细胞、破骨细胞前体和成骨细胞,通过自分泌/旁分泌机制促进破骨细胞生成。